Contrast-enhanced MRI lesions during treatment with interferonβ-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis

Katrin Morgen, A. L T Crawford, R. D. Stone, R. Martin, N. D. Richert, J. A. Frank, H. F. McFarland

Research output: Contribution to journalArticlepeer-review

Abstract

T1 black holes (BH) have been found to represent focal areas of substantial central nervous system tissue damage in multiple sclerosis (MS) patients. We examined the development of T1 BH over a three-year period of treatment with interferon (IFN)β-1b in a group of 20 patients with relapsing-remitting MS. The number of contrast-enhancing lesions (CEL) after one year of treatment predicted a change in the T1 BH volume in the following two years. In patients without CEL, the T1 BH volume remained stable, whereas it increased in patients with CEL. The occurrence of CEL in patients treated with IFNβ may indicate a heightened risk of accumulating T1 BH.

Original languageEnglish (US)
Pages (from-to)146-148
Number of pages3
JournalMultiple Sclerosis
Volume11
Issue number2
DOIs
StatePublished - Apr 2005
Externally publishedYes

Keywords

  • Black holes
  • Contrast-enhancing lesions
  • IFNβ-1b
  • Relapsing-remitting MS

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Contrast-enhanced MRI lesions during treatment with interferonβ-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this